ISSN 2320 - 2602
Volume 13 No. 1, January 2024
International Journal of Advances in Computer Science and Technology
Available Online at http://www.warse.org/IJACST/static/pdf/file/ijacst021312024.pdf
https://doi.org/10.30534/ijacst/2024/021312024

Smart Synergy: Harnessing Machine Learning for Advanced Nanotechnology in Healthcare

Dr. Chandra Naik[1], Monisha M[2], Nanda C B[3], Bhoomika M P[4], Swathi M V[5]
[1]Alva's Institute of Engineering and Technologies, India, chandranaik@aiet.org.in
[2]Alva's Institute of Engineering and Technologies, India, 4al20cs081@gmail.com
[3]Alva's Institute of Engineering and Technologies, India, bangernanda@gmail.com
[4]Alva's Institute of Engineering and Technologies, India, bhoomibhoomikamp@gmail.com
[5]Alva's Institute of Engineering and Technologies, India, 4al20cs158@gmail.com

Received Date : November 28 , 2023 Accepted Date : December 28, 2023 Published Date : January 07, 2024

ABSTRACT

Nanotechnology has emerged as a transformative field with immense potential for revolutionizing healthcare by enabling precise diagnostics, targeted drug delivery, and innovative therapeutic approaches. The integration of machine learning (ML) with nanotechnology holds promise in overcoming existing challenges and unlocking new frontiers in personalized medicine and disease management. This paper explores the synergies between machine learning and next-generation nanotechnology applications in healthcare. Medical applications of nanotechnology are maturing, but automated composite design faces unique challenges. To realize the full potential of nano-delivery systems and accelerate the development process, new ideas require the use of learning models, although machine learning has made it possible to influence this in the scientific literature.

Key Words: Nanotechnology, Harnessing, Data, Machine Learning

1. INTRODUCTION

Though it has many practical uses in a variety of economic sectors, nanotechnology has just lately become widely used in the healthcare industry [1]. For instance, the widely used COVID-19 vaccines from Moderna and BioNTech/Pfizer deliver SARS-CoV-2 mRNA using organic nanoparticles [2]. The search for this innovative vaccination method has brought nanotechnology to the forefront of interest, offering a wealth of clinical evidence and encouraging its application in a variety of disease areas, such as cancer. In this sense, years of spending billions of dollars on basic and translational nanotechnology have made it possible to comprehend the design principles that underpin efficacy [1]. The expected transition to nanotechnology-cantered molecular medicine will require the effective use of technological tools in the ever-expanding field of knowledge.[11] It is not far off to see information-driven evolution similar to what we already see in biology and chemistry.[12] We believe that the new design of integrated nano-delivery systems and predictive modelling will become a whole and lead to a new era in nanotechnology research. In this paper, we examine how machine learning (ML) will transform the delivery of medicine to patients in the future and three challenges that different/advanced nanotechnology must overcome.[14]

2. CHALLENGES

Challenges faced in harnessing machine learning for advanced nanotechnology in healthcare

2.1 Standardized reporting of data

Any machine learning tool must have high-quality data as its foundation, and it is well recognized that the fields of nanobiotechnology and nanomedicine currently lack regular reporting procedures (Figure 1) [3] This prevents meaningful comparison studies and repeatability, even in the face of a recent community effort to control and enhance transparency in the released materials. For instance, the administration dose, loading in drug delivery systems, and physicochemical characteristics (such as dimension, shape, surface charge, targeting agent density, and composition) are key factors in modifying pharmacokinetics and efficacy.[13] But the lack of clear information in their publications or the variability of their reporting undermines the momentum that nanomedical research is gaining [4]. Furthermore, we contend that although precise reporting of the precise composition, injection volume, concentration, and administration method is necessary, it should only be done sparingly. A number of studies additionally detail the dosage of a single component in the delivery system, such as iron or an encapsulated medication.[15] It is therefore nearly impossible to normalize the others by body weight in in vivo experiments. Similar to the difficulties in the characterization of nano delivery materials, there are also flaws in the assay endpoint report.[16] Tumour accumulation and delivery efficacy are typically expressed as a %ID/g, or initial dose divided by tumour mass. This is only helpful if the tumour mass and initial dosage are also disclosed, which is not often the case.[17]

Additionally, percent tumour reduction is an endpoint measure that does not provide information about delivery quality or variability. Finally, it should be remembered that animal models represent real diseases and experiments should be carefully designed to ensure effectiveness.[18] Also, they may not be suitable for replicating the disease and tumour microenvironment such as using a xenograft/allograft ectopic model from an orthotopic model (e.g., subcutaneous injection of lung cells.) >In general, nanomaterials are difficult to fabricate, and established practices in experimental characterization are insufficient to support further clinical translation.[19] The implementation of these practices will ultimately lead to innovation and research.



Figure 1: Schematic representation of the key issues to be addressed during nano-delivery system development and proposed solutions for continued innovation and increased productivity.

It is generally accepted that any machine learning system must have a solid foundation of good data, as shown in Figure 1. However, there are differences between the methods regularly published in the field of nanobiotechnology and nanomedicine. The data modelling guidelines suggested in MIRIBEL Guide 4 will generate the best data for statistical models. These include information on aggregates (e.g., loading, coating), physicochemical properties (e.g., size, zeta potential, shape), bioassay readouts, pharmacokinetics and annotation. We believe that the use of natural language processing (NLP) can help create open data that can be used for overall analysis and support the development of new websites and/or integrated data.[5] Additionally, the development of new canonical representations of chemical compounds will aid in the development of machine learning models for functional prediction and design of nanotechnology products as a guide to the in-silico design of nanomaterials.[20] In order for the relevant equipment to be independent and integrated into robotic systems, it must comply with the "Financeable, Accessible, Interoperable and Reusable" (FAIR) principles and the equipment must complete the design-build-test process. We hope that the move to strong reporting standards will facilitate the development of nano-delivery devices.

2.2 Complete the information

As mentioned above, successful publication will help create a nanotechnology repository similar to Chambly. To highlight the importance of quality and complete information, we extracted the content, physical chemistry, pharmacokinetics, and dosage of iron oxide nanoparticles reported in 315 research articles published in reputable nanotechnology journals between 2006 and 2019. From those, 68% did not report the size, shape, or zeta potential of the nanoparticles. Further, only 1% and 31% presented a pharmacokinetics profile (with elimination/distribution half-lives and delivery efficiency) and dosing information (route and dose), respectively. The method clearly varies with other types of nanoparticles. We found that 51% and 45% of 322 gold and 257 silica nanoparticle studies, respectively, failed to achieve physical fitness. The same percentage of pharmacokinetic and dosing data were found to be missing.[21] All of this highlights the profound limitations that the field of nanotechnology must address.[6] Until then, the design will require the entry or destruction of important data, which is far from ideal.[22] Although public resources will not be available even with adequate guidance in the coming years, we hope that the support and cooperation of the society will be important in achieving this goal. These efforts can be further supported by natural language processing and deep learning, allowing by incorporating many undiscovered patterns, this data should support automated processes and enable early testing by supporting the use of machine learning tools.[7]

2.3 Machine-readable nanotechnology language

While predictive modelling 8,9 can be done using good data and design heuristics, the design of mixed data requires the development of new tools. In a minor exploration, the SMILES or SELFIES10 language encodes the atomic connection that implicitly binds all the physicochemical and biological properties of a particular thing.[23] By learning these words, computers can create new words/molecules (in strings) as follows: The probability will be distributed for each new character added.[8] In the process, scientists learned the power of obtaining new drugs and exploring vast areas. We believe that a similar approach can be devoted to the design and processing of mixed distribution products (Figure 1). Consideration of compositional data, including which entities, their percentages and/or concentrations, is important to determine all possible physicochemical properties and concentrations.[9] Due to biological material, it becomes important to jointly represent a new language and ontology, both of which have already been published and evaluated on computers.[10] The description should represent nanomaterials as a whole and will therefore be adaptable to all applications beyond the drug delivery systems we focus on here. Once these technologies are well known, the research community will have access to untapped concepts for the new production of compounds. We hope that, when used correctly, machine learning models (which will be available in the short/medium term) can impact medical nanotechnology in the same way they are changing research chemistry.[10] Overall, we expect nanotechnology research to gain momentum and look forward to future developments that leverage machine learning ideas.[24] Our solution to our competitive advantage is clearly still unresolved by the scientific community. We hope that the tight integration of computer and robotics will lead to an era of digital nanotechnology, which will see new models and life-changing treatments. time the time must be completed in the present tense.[25]

3. CONCLUSION

In conclusion, the convergence of machine learning and next-generation nanotechnology in healthcare represents a paradigm shift towards unprecedented innovation and precision. The marriage of intelligent algorithms with advanced nanoscale technologies has demonstrated the ability to surpass traditional boundaries, offering solutions that are more personalized, efficient, and effective. The concept of "Smart Synergy" encapsulates not only the collaborative power of these technologies but also their harmonious integration to address complex healthcare challenges. As we navigate this frontier, it is essential to acknowledge and address challenges related to data privacy, interpretability, and ethical considerations. Responsible development and deployment will be paramount to ensuring the seamless adoption of these technologies in real-world healthcare settings. Moreover, ongoing research and development efforts should focus on refining algorithms, enhancing model interpretability, and establishing robust ethical frameworks. Looking ahead, the future holds exciting possibilities, including adaptive nanodevice design, smart nano systems, and the incorporation of real-time patient data for personalized healthcare solutions. The path to unlocking the potential of this intelligent system requires interdisciplinary collaboration and the promotion of effective approaches to new treatments. In summary, “Smart Collaboration: Leveraging Machine Learning to Enable Advanced Nanotechnologies in Healthcare” not only demonstrates the current state of transformational collaboration but also lays the groundwork for the power and future promise of machine learning. and the integration of nanotechnology is pushing medicine into an unprecedented domain of precision, quality of efficiency, and regulatory compliance.

REFERENCES

1. Talebian, S., Rodrigues, T., das Neves, J., Sarmento, B., Langer, R., and Conde, J. (2021). Facts and Figures on Materials Science and Nanotechnology Progress and Investment. ACS Nano. https://doi.org/10. 1021/acsnano.1021c03992.
2. Talebian, S., and Conde, J. (2020). Why Go NANO on COVID-19 Pandemic? Matter 3, 598–601.
3. Schrurs, F., and Lison, D. (2012). Focusing the research efforts. Nat. Nanotechnol. 7, 546–548.
4. Faria, M., Bjo¨ rnmalm, M., Thurecht, K.J., Kent, S.J., Parton, R.G., Kavallaris, M., Johnston, A.P.R., Gooding, J.J., Corrie, S.R., Boyd, B.J., et al. (2018). Minimum information reporting in bio-nano experimental literature. Nat. Nanotechnol. 13, 777–785.
5. Conde, J. (2020). Above and Beyond Cancer Therapy: Translating Biomaterials into the Clinic. Trends Cancer 6, 730–732.
6. Gaulton, A., Hersey, A., Nowotka, M., Bento, A.P., Chambers, J., Mendez, D., Mutowo, P., Atkinson, F., Bellis, L.J., Cibria´n-Uhalte, E., et al. (2017). The ChEMBL database in 2017. Nucleic Acids Res. 45 (D1), D945–D954.
7. O¨ ztu¨rk, H., O¨ zgu¨r, A., Schwaller, P., Laino, T., and Ozkirimli, E. (2020). Exploring chemical space using natural language processing methodologies for drug discovery. Drug Discov. Today 25, 689–705.
8. Tao, H., Wu, T., Aldeghi, M., Wu, T.C., Aspuru-Guzik, A., and Kumacheva, E. (2021). Nanoparticle synthesis assisted by machine learning. Nat. Rev. Mater. 6, 701–716.
9. Hart, G.L.W., Mueller, T., Toher, C., and Curtarolo, S. (2021). Machine learning for alloys. Nat. Rev. Mater. 6, 730–755.
10. Krenn, M., Ha¨ se, F., Nigam, A., Friederich, P., and Aspuru-Guzik, A. (2020). Self-referencing embedded strings (SELFIES): A 100% robust molecular string representation. Mach. Learn. Sci. Technol. 1, 045024.
11. K. Puri, H. D. Allen, and A. M. Qureshi, “congenital heart disease,” Pediatrics in Review, vol. 38, no. 10, pp. 471–486, 2017.
12. M. A. Abdullah, F. Mukhtar, S. Wazir, I. Gilani, Z. Gorar, and B. T. Shaikh, “The health workforce crisis in Pakistan: a critical review and the way forward,” World Health & Population, vol. 15, no. 3, pp. 4–12, 2014. Journal of Nanomaterials 13
13. S. R. Bhatikar, C. DeGro ff, and R. L. Mahajan, “A classi fier based on the arti ficial neural network approach for cardiologic auscultation in pediatrics,” Artificial Intelligence in Medicine, vol. 33, no. 3, pp. 251 –260, 2005.
14. T. Cochrane, “Review manager (RevMan) 5.3,” Copenhagen: the Nordic Cochrane Centre, vol. 373, 2008.
15. G. S. Collins, J. B. Reitsma, D. G. Altman, K. G. M. Moons, and TRIPOD Group, “Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD),” Circulation, vol. 131, no. 2, pp. 211–219, 2015.
16. J. P. De Vos and M. M. Blanckenberg, “Automated pediatric cardiac auscultation,” IEEE Transactions on Biomedical Engineering, vol. 54, no. 2, pp. 244–252, 2007.
17. C. G. DeGro ff, S. Bhatikar, J. Hertzberg, R. Shandas, L. ValdesCruz, and R. L. Mahajan, “Artificial neural network-based method of screening heart murmurs in children, ” Circulation , vol. 103, no. 22, pp. 2711 – 2716, 2001
18. P. J. Isaac, S. Amaravadi, K. MSM, and C. KK, “Synthesis of zeolite/activated carbon composite material for the removal of lead (II) and cadmium (II) ions,” Environmental Progress and Sustainable Energy, vol. 38, no. 6, article e13246, 2019.
19. L. J. Points, J. W. Taylor, J. Grizou, K. Donkers, and L. Cronin, “Artificial intelligence exploration of unstable protocells leads to predictable properties and discovery of collective behavior,” Proceedings of the National

Academy of Sciences, vol. 115, no. 5, pp. 885 –890, 2018.

20. Z. Hoodbhoy, U. Jiwani, S. Sattar, R. Salam, B. Hasan, and J. K. Das, "Diagnostic accuracy of machine learning models to identify congenital heart disease: a meta-analysis," Frontiers in Artificial Intelligence, vol. 8, no. 4, article 708365, 2021.
21. S. Nurmaini, M. N. Rachmatullah, A. I. Sapitri et al., "Deep learning-based computer-aided fetal echocardiography: application to heart standard view segmentation for congenital heart defects detection," Sensors, vol. 21, no. 23, article 8007, 2021.
22. D. Naveen Kilari, A. H. Sekhar, N. S. Reddy, and N. P. Dharani, "A 3 - Φ grid connected wind system with a technique of DC link control using fewer sensors with fuzzy controller," International Journal of Intelligent Unmanned Systems, vol. 2, no. 3, 2021.
23. G.-P. Diller, A. Kempny, S. V. Babu-Narayan et al., "Machine learning algorithms estimating prognosis and guiding therapy in adult congenital heart disease: data from a single tertiary centre including 10 019 patients," European Heart Journal, vol. 40, no. 13, pp. 1069 –1077, 2019.
24. J. Grizou, L. J. Points, A. Sharma, and L. Cronin, "A curious formulation robot enables the discovery of a novel protocell behavior," Science Advances, vol. 6, no. 5, article eaay4237, 2020.
25. R. O. Bahado-Singh, S. Vishweswaraiah, B. Aydas et al., "Precision cardiovascular medicine: artificial intelligence and epigenetics for the pathogenesis and prediction of coarctation in neonates," The Journal of Maternal-Fetal & Neonatal Medicine, vol. 35, no. 3, pp. 457–464, 2020